Post COVID-19 condition and its physical, mental and social implications: protocol of a 2-year longitudinal cohort study in the Belgian adult population.

COVID-19 Health Longitudinal study Post COVID-19 condition Symptoms

Journal

Archives of public health = Archives belges de sante publique
ISSN: 0778-7367
Titre abrégé: Arch Public Health
Pays: England
ID NLM: 9208826

Informations de publication

Date de publication:
04 Jun 2022
Historique:
received: 21 01 2022
accepted: 24 05 2022
entrez: 6 6 2022
pubmed: 7 6 2022
medline: 7 6 2022
Statut: epublish

Résumé

Since the onset of the COVID-19 pandemic, most research has focused on the pathophysiology and management of the acute symptoms of COVID-19, yet some people tend to experience symptoms beyond the acute phase of infection, that is, Post COVID-19 condition (PCC). However, evidence on the long-term health impacts of a COVID-19 infection are still scarce. The purpose of this paper is to describe the COVIMPACT study, which aims to set up a cohort of people who have been tested positive for COVID-19 and study the evolution of their physical, mental and social health over the medium (3 months) and long term (two years), and the factors associated with an (un)favorable evolution. COVIMPACT is a longitudinal cohort study organised over a two-years period between April 2021 and April 2023. The eligible population is all people aged 18 years and older, living in Belgium, with a recent COVID-19 infection and contacted by the health authorities for contact tracing. Two questionnaires are used: a baseline questionnaire that aims to assess the initial health status of the participants and their status during the acute phase of the illness, and a follow-up questionnaire that is sent every three months after participants enter into the cohort. A matched non-COVID-19 control group was also selected. As of November 1, 2021, 10,708 people completed the baseline questionnaire (5% of the eligible population) and the follow-up participation rate was 79%. In total, 48% of the cohort participants appeared to fit the proposed case definition of PCC (i.e. report at least one symptom related to their COVID-19 infection three months afterwards). This study was designed to provide timely information on the short and long term impact of a COVID-19 infection, to stakeholders such as policymakers, health practitioners and people with PCC. Although the follow-up participation rate was good (79%), the participation rate of the eligible population was low (5%). Compared to other studies, this study has a large sample, of non-hospitalised and hospitalised people, who will be followed over a long period of 3 months to two years post infection, and with a global approach to their health.

Sections du résumé

BACKGROUND BACKGROUND
Since the onset of the COVID-19 pandemic, most research has focused on the pathophysiology and management of the acute symptoms of COVID-19, yet some people tend to experience symptoms beyond the acute phase of infection, that is, Post COVID-19 condition (PCC). However, evidence on the long-term health impacts of a COVID-19 infection are still scarce. The purpose of this paper is to describe the COVIMPACT study, which aims to set up a cohort of people who have been tested positive for COVID-19 and study the evolution of their physical, mental and social health over the medium (3 months) and long term (two years), and the factors associated with an (un)favorable evolution.
METHODS METHODS
COVIMPACT is a longitudinal cohort study organised over a two-years period between April 2021 and April 2023. The eligible population is all people aged 18 years and older, living in Belgium, with a recent COVID-19 infection and contacted by the health authorities for contact tracing. Two questionnaires are used: a baseline questionnaire that aims to assess the initial health status of the participants and their status during the acute phase of the illness, and a follow-up questionnaire that is sent every three months after participants enter into the cohort. A matched non-COVID-19 control group was also selected. As of November 1, 2021, 10,708 people completed the baseline questionnaire (5% of the eligible population) and the follow-up participation rate was 79%. In total, 48% of the cohort participants appeared to fit the proposed case definition of PCC (i.e. report at least one symptom related to their COVID-19 infection three months afterwards).
DISCUSSION CONCLUSIONS
This study was designed to provide timely information on the short and long term impact of a COVID-19 infection, to stakeholders such as policymakers, health practitioners and people with PCC. Although the follow-up participation rate was good (79%), the participation rate of the eligible population was low (5%). Compared to other studies, this study has a large sample, of non-hospitalised and hospitalised people, who will be followed over a long period of 3 months to two years post infection, and with a global approach to their health.

Identifiants

pubmed: 35659364
doi: 10.1186/s13690-022-00906-2
pii: 10.1186/s13690-022-00906-2
pmc: PMC9166244
doi:

Types de publication

Journal Article

Langues

eng

Pagination

151

Informations de copyright

© 2022. The Author(s).

Références

Int J Environ Res Public Health. 2020 Dec 14;17(24):
pubmed: 33327641
Pathogens. 2022 Feb 19;11(2):
pubmed: 35215212
J Clin Med. 2021 Jul 27;10(15):
pubmed: 34362088
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Thorax. 2021 Apr;76(4):405-407
pubmed: 33273028
PLoS One. 2020 Dec 11;15(12):e0243882
pubmed: 33306721
Rhinology. 2021 Dec 1;59(6):517-527
pubmed: 34553706
BMJ Glob Health. 2021 Sep;6(9):
pubmed: 34580069
medRxiv. 2021 Mar 05;:
pubmed: 33688670
Clin Infect Dis. 2021 Aug 2;73(3):e826-e829
pubmed: 33624010
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
Res Sq. 2021 Mar 01;:
pubmed: 33688642
Int J Clin Pract. 2021 Oct;75(10):e14357
pubmed: 33977626
Clin Infect Dis. 2022 Apr 9;74(7):1191-1198
pubmed: 34223884
Eur J Intern Med. 2021 Oct;92:55-70
pubmed: 34167876
Arch Public Health. 2022 Apr 13;80(1):118
pubmed: 35418097
Public Opin Q. 2001 Summer;65(2):230-53
pubmed: 11420757
Arch Public Health. 2021 Oct 27;79(1):188
pubmed: 34706768
Int Forum Allergy Rhinol. 2021 Dec;11(12):1685-1688
pubmed: 34109765
Clin Microbiol Infect. 2021 Feb;27(2):258-263
pubmed: 33031948
JAMA. 2021 Apr 20;325(15):1525-1534
pubmed: 33729425
J Glob Health. 2020 Dec;10(2):020506
pubmed: 33110589
Nature. 2020 Sep;585(7825):339-341
pubmed: 32929257
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Int J Infect Dis. 2020 Nov;100:327-332
pubmed: 32920235
Ann Intern Med. 2021 May;174(5):723-725
pubmed: 33284676
J Clin Med. 2021 Jun 30;10(13):
pubmed: 34209085
Sci Rep. 2021 Aug 9;11(1):16144
pubmed: 34373540

Auteurs

Pierre Smith (P)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium. pierre.smith@sciensano.be.
Institute of Health and Society (IRSS), Université Catholique de Louvain, Brussels, Belgium. pierre.smith@sciensano.be.

Kristiaan Proesmans (K)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.

Dieter Van Cauteren (D)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.

Stefaan Demarest (S)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.

Sabine Drieskens (S)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.

Robby De Pauw (R)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium.

Laura Cornelissen (L)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.

Karin De Ridder (K)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.

Rana Charafeddine (R)

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.

Classifications MeSH